Table II.

Effects of low-dose RTX on lymphocyte counts and CD20 levels

PatientRTX (mg/m2)ALCaCD20b
Pre-RxPost-RxPercentage of reductioncStartFinishPercentage of shavedd
12060887271256
22089298196NDBe
320612067211338
1020424901027427
1120645219724833
1220744314379
46086217619289
56064413642686
6601037032294
76097178223483
860120.893554NDBe
96021171926485
  • a One thousand per microliter prior to first, and at the start of twelfth RTX infusion (11 of 12 patients) or sixth infusion (patient 9). NBD, No detectable B cells.

  • b CD20 levels prior to first, and at the start of twelfth RTX infusion (11 of 12 patients) or sixth infusion (patient 9) (MESF × 10−3).

  • c Mean and SD for 20 and 60 mg/m2 groups, respectively; 67 ± 31 and 63 ± 29%.

  • d Mean and SD for 20 and 60 mg/m2 groups, respectively; 47 ± 21 and 87 ± 4% (p = 0.0026). If patient 12 is omitted, the value for the 20 mg/m2 groups is 39 ± 13% (p < 0.001).

  • e Patients 2 and 8 were not included in the calculation of percentage of shaved.